About Serine incorporator 4
Serine incorporator 4 (SERINC4) is a protein
from Homo sapiens identified by UniProt accession
A6NH21, 518 residues long.
MolForge cross-references it against 0 known binders and
7 disease associations.
Target properties
| Protein name | Serine incorporator 4 |
| UniProt accession | A6NH21 |
| Gene | SERINC4 |
| Organism | Homo sapiens |
| Length | 518 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (7)
Diseases linked to this target (Open Targets).
- hemoglobin A1 measurement · score 0.03
- blood protein measurement · score 0.03
- triglyceride measurement · score 0.03
- high density lipoprotein cholesterol measurement · score 0.02
- susceptibility to urinary tract infection measurement · score 0.02
- type 2 diabetes mellitus · score 0.02
- neoplasm · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-A6NH21-F1 | alphafold | PREDICTED | 71.40 | — |
Amino-acid sequence (518 residues)
MVGAKAGPSP GTSLGLAQQH SGGSSVLVKS PFCQVCCCGP APCASCCHSR WPSLTASTCS RLFYILLHVG ASAICCLLLS RTVVERVWGK THRIQMPSGL CAHLFGLSDC PVLSGSGAVY RVCAGTATFH LLQAVLLVHL HSPTSPRAQL HNSFWLLKLL FLLGLCAIAF CIPDEHLFPA WHYIGICGGF AFILLQLVLI TAFAHSWNKN WQTGAAQDCS WFLAVLLATL GFYSMAGVGA VLLFHYYTHP AGCLLNKMLL SLHLCFCGLI SFLSIAPCIR LKQPRSGLLQ ASVISCYIMY LTFSALSSRP PERVILQGQN HTLCLPGLSK MEPQTPDISL AMLSASIMYA CVLFACNEAS YLAEVFGPLW IVKVYSYEFQ KPSLCFCCPE TVEADKGQRG GAARPADQET PPAPPVQVQH LSYNYSAFHF VFFLASLYVM VTLTNWFSYE GAELEKTFIK GSWATFWVKV ASCWACVLLY LGLLLAPLCW PPTQKPQPLI LRRRRHRIIS PDNKYPPV
Explore Serine incorporator 4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets